Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2017

  • ID: 4399928
  • Clinical Trials
  • Region: Global
  • 834 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • MORE
Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2017

Summary

The clinical trial report, “Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2017" provides an overview of Glioblastoma Multiforme (GBM) clinical trials scenario. This report provides top line data relating to the clinical trials on Glioblastoma Multiforme (GBM). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using the author’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • MORE
Report Guidance
Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Glioblastoma Multiforme (GBM)
Nov 13, 2017: Theralase Researcher Discovers Super Potent Anti-Cancer Drugs
Nov 13, 2017: Oncoceutics to Present Data on Glioblastoma Drug Candidate ONC201 at SNO
Nov 09, 2017: Medicenna Announces Presentations at the 2017 Annual Meeting of the Society of Neuro-Oncology
Nov 07, 2017: Nektar to Present New On Drug Candidate NKTR-262 At 2017 Society for Immunotherapy of Cancer 32nd Annual Meeting
Nov 06, 2017: Scientists exploit leaks in blood brain barrier to treat glioblastoma
Nov 06, 2017: ZIOPHARM Announces Four Presentation Abstracts at the 2017 Annual Meeting of the Society for Neuro-Oncology
Oct 17, 2017: Diffusion Pharmaceuticals Receives Final FDA Protocol Guidance for Phase 3 Clinical Trial with TSC in Patients Newly Diagnosed with Inoperable Glioblastoma Multiforme
Oct 12, 2017: Lenox Hill Hospital participates in clinical research study to test investigational treatment for recurrent brain cancer
Oct 11, 2017: Mustang Bio Announces $12.8 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-101 in Malignant Glioma
Oct 11, 2017: Immunomic Therapeutics Offers Travel Fund for Clinical Trial Patients
Oct 10, 2017: Boston Biomedical Announces Orphan Drug Designation by FDA for Investigational WT1 Cancer Peptide Vaccine DSP-7888 in Brain Cancer
Oct 09, 2017: ReNeuron presents positive pre-clinical data with its ExoPr0 exosome cancer therapy candidate at American Society for Exosomes and Microvesicles 2017 Annual Meeting
Sep 29, 2017: National Cancer Institute Awards Grant to NuvOx Pharma for Phase II Clinical Trial in Brain Cancer
Sep 26, 2017: CEO Jeffery Bacha Discusses DelMar's VAL-083 Clinical Trials and the Major Milestones Ahead
Sep 25, 2017: Theralase Lead Anti-Cancer Drug Effective in the Destruction of Brain Cancer when Activated by X-Rays
Sep 14, 2017: Patrys: PAT-DX1 Active in Pre-clinical Cancer Models
Sep 12, 2017: Theralase Theralase Demonstrates Increased Efficacy for Latest Anti-Cancer Drug
Sep 11, 2017: DelMar Pharmaceuticals Initiates Phase 2 Clinical Trial in Newly Diagnosed MGMT-unmethylated Glioblastoma Multiforme
Sep 07, 2017: NCCN Announces First Patient Dosed in NCCN-Peregrine Pharmaceuticals Collaborative Study of Bavituximab
Sep 06, 2017: DelMar Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 10-12, 2017
Sep 01, 2017: DCVax-L Clinical Program Updates Presented By Dr. Marnix Bosch At Boston Scientific Conference
Aug 30, 2017: Bristol-Myers Squibb Data at ESMO 2017 Demonstrate Company's Innovative Research Approach to Treating Cancer from All Angles
Aug 28, 2017: VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit
Aug 22, 2017: GDC-0084 Progress Update: On Track for Phase II Commencement in 2017
Aug 22, 2017: Curtana Pharmaceuticals Successfully Completes Pre-IND Submission for CT-179 for the Treatment of Malignant Gliomas
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About
Contact
Disclaimer
Source

List of Tables
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Region, 2017*
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, North America, Top Countries, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017*
Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, G7 Countries (%), 2017*
Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, E7 Countries (%), 2017*
Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Phase, 2017*
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Phase 2017*
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Trial Status, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, by End Point Status, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Glioblastoma Multiforme (GBM) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*

List of Figures
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Region (%), 2017*
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, North America, Top Countries (%), 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017*
Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, G7 Countries (%), 2017*
Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, E7 Countries (%), 2017*
Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Phase (%), 2017*
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017*
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Trial Status, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, by End Point Status, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Glioblastoma Multiforme (GBM) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
Methodology
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • F. Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • Pfizer Inc
  • Novartis AG
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Eli Lilly and Co
  • Sarah Cannon Research Institute LLC
  • AbbVie Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll